Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2024 | 166 | 1.860 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2025 | 1264 | 1.690 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2020 | 125 | 1.150 |
Why?
|
| Calcineurin Inhibitors | 2 | 2024 | 25 | 1.060 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2022 | 577 | 1.030 |
Why?
|
| Immune Tolerance | 2 | 2025 | 153 | 1.010 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2023 | 132 | 0.860 |
Why?
|
| Graft vs Host Disease | 3 | 2025 | 685 | 0.840 |
Why?
|
| T-Lymphocytes | 5 | 2025 | 1694 | 0.750 |
Why?
|
| Albumins | 1 | 2022 | 89 | 0.720 |
Why?
|
| Leukemia | 1 | 2023 | 374 | 0.640 |
Why?
|
| Nutrition Assessment | 1 | 2020 | 126 | 0.610 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2019 | 9 | 0.610 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 450 | 0.600 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2019 | 37 | 0.590 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2019 | 58 | 0.580 |
Why?
|
| Nutritional Status | 1 | 2020 | 301 | 0.570 |
Why?
|
| Hemorrhagic Disorders | 1 | 2018 | 24 | 0.560 |
Why?
|
| Empyema, Pleural | 1 | 2018 | 26 | 0.550 |
Why?
|
| Ferritins | 1 | 2018 | 108 | 0.540 |
Why?
|
| Giant Cell Arteritis | 1 | 2018 | 49 | 0.520 |
Why?
|
| Transplantation, Homologous | 4 | 2025 | 673 | 0.460 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 294 | 0.440 |
Why?
|
| Herpesvirus 4, Human | 1 | 2018 | 644 | 0.440 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6773 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2097 | 0.340 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2020 | 80 | 0.300 |
Why?
|
| Prognosis | 4 | 2024 | 4927 | 0.290 |
Why?
|
| Japan | 3 | 2024 | 166 | 0.240 |
Why?
|
| Humans | 18 | 2025 | 130574 | 0.220 |
Why?
|
| Transplantation Tolerance | 1 | 2024 | 11 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1320 | 0.220 |
Why?
|
| Bile Ducts | 1 | 2024 | 53 | 0.210 |
Why?
|
| Extracellular Traps | 1 | 2024 | 11 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2024 | 26 | 0.210 |
Why?
|
| Aged | 6 | 2024 | 20925 | 0.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2024 | 91 | 0.200 |
Why?
|
| Retrospective Studies | 6 | 2023 | 17653 | 0.200 |
Why?
|
| Allografts | 1 | 2024 | 218 | 0.200 |
Why?
|
| Exosomes | 1 | 2024 | 62 | 0.200 |
Why?
|
| Cyclosporine | 1 | 2023 | 131 | 0.190 |
Why?
|
| Animals | 7 | 2025 | 33899 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 136 | 0.190 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2022 | 60 | 0.180 |
Why?
|
| Myeloproliferative Disorders | 1 | 2023 | 93 | 0.180 |
Why?
|
| Azacitidine | 1 | 2022 | 52 | 0.180 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2022 | 39 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 456 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2023 | 163 | 0.170 |
Why?
|
| Neutropenia | 1 | 2022 | 202 | 0.170 |
Why?
|
| Tissue Donors | 1 | 2025 | 501 | 0.170 |
Why?
|
| Organoids | 1 | 2024 | 306 | 0.170 |
Why?
|
| Mice | 5 | 2024 | 18224 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 219 | 0.170 |
Why?
|
| Spinal Cord Injuries | 1 | 2024 | 277 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 311 | 0.150 |
Why?
|
| Hospitals, General | 1 | 2018 | 24 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 292 | 0.140 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 164 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2019 | 239 | 0.140 |
Why?
|
| Male | 7 | 2024 | 64557 | 0.140 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2018 | 126 | 0.130 |
Why?
|
| ROC Curve | 1 | 2019 | 616 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2024 | 901 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
|
| RNA, Messenger | 4 | 2023 | 2556 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 1150 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 690 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 364 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 837 | 0.110 |
Why?
|
| Anemia | 1 | 2018 | 354 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1154 | 0.090 |
Why?
|
| Antibodies, Viral | 3 | 2023 | 1165 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2020 | 3712 | 0.080 |
Why?
|
| Middle Aged | 3 | 2024 | 28448 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12891 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 4034 | 0.080 |
Why?
|
| Female | 4 | 2024 | 70509 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2020 | 6475 | 0.080 |
Why?
|
| Young Adult | 2 | 2024 | 9991 | 0.070 |
Why?
|
| Neoplasms | 1 | 2023 | 2951 | 0.070 |
Why?
|
| Vaccination | 2 | 2023 | 1033 | 0.070 |
Why?
|
| Adult | 3 | 2024 | 31202 | 0.060 |
Why?
|
| Dioxoles | 1 | 2024 | 13 | 0.050 |
Why?
|
| Filgrastim | 1 | 2024 | 13 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2024 | 97 | 0.050 |
Why?
|
| Benzamides | 1 | 2024 | 125 | 0.050 |
Why?
|
| Rituximab | 1 | 2024 | 172 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 364 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 166 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2024 | 235 | 0.050 |
Why?
|
| WT1 Proteins | 1 | 2022 | 23 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2022 | 31 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2022 | 21 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2022 | 127 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 317 | 0.040 |
Why?
|
| Pyrazines | 1 | 2022 | 79 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2022 | 104 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 1136 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 1312 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2022 | 188 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 896 | 0.040 |
Why?
|
| Saliva | 1 | 2020 | 125 | 0.040 |
Why?
|
| Stem Cells | 1 | 2024 | 711 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 496 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 752 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 461 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 3412 | 0.030 |
Why?
|
| Liver | 1 | 2024 | 1802 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1268 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5221 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 4701 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2022 | 3835 | 0.030 |
Why?
|
| Mutation | 1 | 2022 | 6139 | 0.020 |
Why?
|